Ligelizumab could top Xolair in chronic hives, says NovartisNovartis’ immunoglobulin E inhibitor Xolair has been a mainstay of treatment for chronic spontaneous urticaria (CSU) for many Share XLigelizumab could top Xolair in chronic hives, says Novartishttps://pharmaphorum.com/news/ligelizumab-could-top-xolair-in-chronic-hives-says-novartis/
Novartis takes Xolair follow-up into phase III hives trialNovartis says it intends to move a drug for chronic spontaneous urticaria (CSU), a severe form of hives, Share XNovartis takes Xolair follow-up into phase III hives trialhttps://pharmaphorum.com/news/novartis-takes-xolair-follow-up-into-phase-iii-hives-trial/
Breakthrough designation for Roche/Novartis’ Xolair in food allergiesXolair, a drug developed 15 years ago by Roche and Novartis, received a breakthrough designation from the US Share XBreakthrough designation for Roche/Novartis’ Xolair in food allergieshttps://pharmaphorum.com/news/breakthrough-designation-for-roche-novartis-xolair-in-food-allergies/
New dermatology licence for XolairXolair has gained EU approval as the first ever add-on therapy to treat chronic spontaneous urticaria (CSU) in Share XNew dermatology licence for Xolairhttps://pharmaphorum.com/news/new-dermatology-licence-for-xolair/
